• CARsgen Therapeutics announced Nov. 5, 2026, that CT1190B and CT071 study abstracts were published ahead of planned ASH poster presentations.
• CT1190B targets relapsed or refractory large B-cell lymphoma; a registrational Phase 1 trial is ongoing.
• CT071 research covers relapsed or refractory multiple myeloma and high-risk newly diagnosed multiple myeloma, with investigator-initiated trials ongoing in China.
• Updated CT0596 results for relapsed or refractory multiple myeloma and primary plasma cell leukemia will be released in December 2026.
• Earlier investigator-initiated CT0596 trials showed preliminary favorable tolerability and encouraging efficacy signals; a registrational Phase 1 multiple myeloma trial is ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261105-12400951), on November 05, 2026, and is solely responsible for the information contained therein.